FHIR © HL7.org  |  Server Home  |  FHIR Server FHIR Server 3.7.21  |  FHIR Version n/a  User: [n/a]

36513311000001108: Ertugliflozin L-pyroglutamic acid (substance)

Status: current, Not sufficiently defined by necessary conditions definition status. Date: 23-Jan 2019. Module: SNOMED CT United Kingdom drug extension module

Descriptions:

Id Description Lang Type Status Case? Module
111636501000001116 Ertugliflozin L-pyroglutamic acid (substance) en Fully specified name Active Entire term case sensitive SNOMED CT United Kingdom drug extension module
111636601000001117 Ertugliflozin L-pyroglutamic acid en Synonym Active Entire term case sensitive SNOMED CT United Kingdom drug extension module

0 descendants.

Expanded Value Set

Outbound Relationships Type Target Active Characteristic Refinability Group Values
Ertugliflozin L-pyroglutamic acid Is a Substance with sodium glucose cotransporter subtype 2 inhibitor mechanism of action true Inferred relationship Existential restriction modifier
Inbound Relationships Type Active Source Characteristic Refinability Group
Ertugliflozin 15mg tablets Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier
Ertugliflozin 5mg tablets Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier
Steglatro 5mg tablets (Merck Sharp & Dohme (UK) Ltd) Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier
Steglatro 15mg tablets (Merck Sharp & Dohme (UK) Ltd) Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier
Ertugliflozin 15mg tablets 28 tablet Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier
Ertugliflozin 5mg tablets 28 tablet Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier
Steglatro 5mg tablets (Merck Sharp & Dohme (UK) Ltd) 28 tablet 4 x 7 tablets Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier
Steglatro 15mg tablets (Merck Sharp & Dohme (UK) Ltd) 28 tablet 4 x 7 tablets Has specific active ingredient True Ertugliflozin L-pyroglutamic acid Inferred relationship Existential restriction modifier

This concept is not in any reference sets

Back to Start